Ascendis Pharma (NASDAQ:ASND) had its price target cut by Wedbush from $76.00 to $67.00 in a research note published on Wednesday morning. They currently have an outperform rating on the biotechnology company’s stock.
ASND has been the topic of a number of other reports. HC Wainwright restated a buy rating on shares of Ascendis Pharma in a report on Friday, January 19th. JPMorgan Chase restated a buy rating and issued a $60.00 target price on shares of Ascendis Pharma in a report on Wednesday, January 17th. Credit Suisse Group restated a buy rating and issued a $50.00 target price on shares of Ascendis Pharma in a report on Sunday, February 25th. Zacks Investment Research upgraded Ascendis Pharma from a strong sell rating to a hold rating in a report on Wednesday, February 21st. Finally, Leerink Swann restated a market perform rating and issued a $64.00 target price (up from $37.00) on shares of Ascendis Pharma in a report on Monday, April 2nd. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $65.83.
Shares of NASDAQ ASND opened at $58.55 on Wednesday. Ascendis Pharma has a 52-week low of $21.95 and a 52-week high of $69.00.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3341035/wedbush-trims-ascendis-pharma-asnd-target-price-to-67-00.html.
About Ascendis Pharma
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries.
Receive News & Ratings for Ascendis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.